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Neuroblastoma
Cydney Keene BSN, RN
Otterbein University, Westerville, Ohio
Introduction
Neuroblastoma is the most common, aggressive extracranial solid malignant type
of cancer found in pediatric patients. “Neuro” refers to the nerves, “blastoma”
indicates the type of cancer affecting immature cells during development, (American
Cancer Society, 2018). Being a Pediatric RN at one of the top Childrens Hospitals, I
often see many types of pediatric cancers in all stages. Neuroblastoma is one that I
have found to be quite interesting due to the fact patients are often under the age of
one year old, and each patient has experienced different effects from their tumor
diagnosis. The exact pathophysiology of the disease is unknown., also making me
curious to read the studies of all the different pathways potentially leading to
Neuroblastoma.

Pathogenesis of Neuroblastoma
Origination begins during intrauterine life, when nerve cells are affected at
their earliest form as a neuroblast, in the sympathetic nerve ganglia of the
abdomen, adrenal glands or the venterolateral neural crest cells.
Neuroblastoma develops when the neuroblasts don’t mature correctly and can
continue growing, creating a tumor. The deregulation of the neural crest tissue
may contribute to the development of tumor cells. The cells that migrate away
from the neural tube, or spine during embryogenesis have the ability to
develop a new phenotype with other ligands throughout the body (Louis et.
al., .2015). Metastasis sites include bone, bone marrow, liver, lungs, brain and
areas of soft tissue. The symptoms the child is experiencing is dependent upon
the location of the tumor and which organs are involved. Due to the migration
of the neural crest cells, the maturation process of these cells can be studied
as precursors to the transformation of malignant cells.
There are multiple different pathways in understanding the
pathophysiology of Neuroblastoma and the specificities of its origin. Studies
are being done on the neural crest tissue and inhibiting the maturation of
malignant tumors and the effectiveness of interventions on a cellular level for
early detection. Chromosomal studies are being performed to identify
instability and the genomic rearrangements within the body. As explained in
table 1, the presence of differentiation and the histology of the tumor and
their specific stage and risk group. Studies are done not only to detect the
disease early, but also determining the aggressiveness and progression of the
disease on a genetic level once diagnosed (Neuroblastoma, 2020). There is no
definitive answer biologically aside from the immaturity of neural crest cells
forming clusters of neuroblasts as a solid malignant tumor.

Stages
There are two International Neuroblastoma staging systems
used to determine the exact phase of the disease. The
International Neuroblastoma Staging System was established
in 1988, using a surgical, pathological staging system to
classify the stages of Neuroblastoma. The International
Neuroblastoma Risk Group Staging System was later developed
in 2009, using imaging results taken before surgery to
determine the stage of the disease, (American Cancer Society,
2018).
International Neuroblastoma Staging System (INSS)
•
Stage 1: tumor is localized with complete gross resection,
lymph node involvement near the tumor may occur
•
Stage 2A: tumor is localized but unable to be resected in
its entirety, no lymph node involvement
•
Stage 2B: tumor is localized, complete resection may or
may occur, ipsilateral lymph node involvement
•
Stage 3: tumor is unable to be resected, metastasis to
lymph nodes near tumor
•
Stage 4: original tumor metastasized to distant lymph
nodes in the bone, bone marrow, liver, skin and other
organs
•
Stage 4S: original tumor is located where it started and
has only spread to the skin, liver and/or bone marrow –
infants less than one year of age. Bone marrow
involvement is minimal with less than 10% of cells testing
positive
International Neuroblastoma Risk Group Staging System
(INRGSS)
•
Stage L1: tumor is located where it started, no image
defined risk factors present in imaging scans
•
Stage L2: tumor has not spread past nearby tissues from
original location, imaging defined risk factors present on
CT or MRI
•
Stage M: tumor has spread to other parts of the body
•
Stage MS: tumor has spread to only the skin, liver, and/or
bone marrow in children under the age of 18 months

Risk Groups
Neuroblastoma is classified into 4 different categories; very low risk, low
risk, intermediate risk or high risk. With the use of The International
Neuroblastoma Risk Group Staging System (INGRSS) and International
Neuroblastoma Staging System (INSS) classification systems and imaging,
risk groups can be predicted. Understanding the risks and behavior of the
tumor, response to treatment can be predicted.
The following factors are used in order to determine the classification of the
tumor:
•
•
•
•
•

•
•

Stage of disease, with use of INRGSS/ INSS
Age at time of diagnosis
Histology
Differentiation of tumor cells
Presence of MYCN oncogene that provides instruction for making a
protein that is important in tissue and organ formation during
embryonic development. When mutated can cause normal cells to
become cancerous.
Chromosome 111q status
DNA content of tumor cells
(Neuroblastoma, 2020)

Clinical Presentation
•
•
•
•
•
•
•
•
•

•
•
•

Abdominal pain
Weight loss, anorexia
Fatigue
Bone pain, limping
Numbness, tingling
Unexplained fever
Irritability
Periorbital ecchymosis
Tumors of the paraspinal sympathetic ganglia can
cause: weakness, limping, paralysis,
bladder/bowel dysfunction
Thoracic tumors are often asymptomatic, but can
cause mild airway obstruction and chronic cough
Infants experience skin lesions similar to rubella
Uncommon effects include diarrhea, hypertension,
myoclonic jerking or rapid eye movements

Statistics
Table 1: Risk Group and Stages of Neuroblastoma
Risk Group

Stage

Age

MYCN
Amplification

Differentiation
and Histology

Low

1

<18 months

Present

Low

2A/2B

< 18 months

Present or
Absent

Favorable or
Unfavorable
Favorable or
Unfavorable

Low

4S

<12 months

none

Favorable

Low

L2

< 18 months

none

11q

Low

M

< 18 months

None

None

Intermediate

2A/2B

<12 months

Present

Favorable or
Unfavorable

Intermediate

3

< 18 months
>18 months

None
None

None
Favorable

Intermediate

4

<12 months
12-18 months

None
None

None
None

Intermediate

4S

<12 months

None

Unfavorable

Intermediate

M

<18 months
>18 months

Present
None

None
None

Intermediate

MS

<18 months

Present or
Absent

11q

High

2A/2B

<18 months

Present

Favorable or
Unfavorable

High

L1/L2

<18 months

Present

Favorable or
Unfavorable

High

4S

< 12 months

Present

Favorable or
Unfavorable

High

M

<18 months
>18 months

Present
None

None
None

High

MS

<18 months

Present

11q

Nursing Implications
Nurses are responsible for checking each patients chemotherapy
road map with a second Chemo Certified Registered Nurse. The purpose
of the road map is to verify that the medications being administered
are appropriate during the specific week of chemotherapy they are in.
Each patient has their own precise configuration of chemotherapy
agents specific to their tumor growth, presence or absence of
metastasis and the impending side effects. Infection, bleeding, and
mucositis are three main symptoms to monitor closely during all stages
of their treatment plan.
Continuous monitoring of each patients blood count, pain control,
electrolyte and hydration status are key responsibilities of Nurses
caring for children with Neuroblastoma due to all the side effects of
their treatments and the aggressiveness of the tumor cells. Observing
the patient after initiation of treatment for adverse effects and/or
allergic reactions will allow their treatment to be adjusted to better
treat their tumor with lesser adverse effects.

• Most common cancer in children
under the age of 1 year old
• 50-60% if children experience
metastasis.
• Occurs more in White, NonHispanic boys
• Neuroblastoma is 6% of all
childhood cancers
• 800 new cases per year
• 90% of children are diagnosed by
age 5, rarely found in children
over 10 years old
• 75% of children already have
lymph node involvement when
diagnosed

Conclusion

Image 1: Metastatic Neuroblastoma of the upper tibia and lower
femur, (Adrenal Gland: Widely Metastatic Neuroblastoma in a 4
year old boy, (2008)[image])

Treatment
Imaging
•
Chest/abdominal x ray
•
CT of primary site and full body scan for metastasis
•
MRI determines if the tumor is intraspinal or causing spinal
cord compression
•
MIBG scan identify primary and metastatic tumor
•
Bone scans evaluate if tumor cells metastasized to the bone
•
Skeletal survey will display metastatic lesions
Surgery
•
Biopsies of the tumor site and surrounding tissue
•
First line cure for localized tumors
•
Metastasized tumors require biopsy for diagnosis and
staging
•
Resection following chemotherapy
Radiation
Chemotherapy is based on the stage of tumor cell growth and
how the medication will affect tumor growth.
•
Antineoplastics interfere with cell production
•
Colony Stimulating factors are used in combination with
other medications to prevent neutropenia
•
Chemoprotective agents are included in the medication
regimen to minimize side effects of the chemo

Neuroblastoma is an aggressive
cancer affecting nearly 800 newly
diagnosed children per year, (Key
Statistics, 2020). The pathogenesis
is studied at a cellular level in
utero to the development of
multiple different pathways, and
the ability to metastasize to
different areas of the body. In
every 2 out of 3 cases, lymph node
involvement was present at the
time of diagnosis. From a genetic
or chromosomal level, to the
maturation of an immature cell
forming a solid malignant mass,
each Neuroblastoma case displays
different side effects requiring
different treatment combinations
and interventions. By improving
diagnosis and discovering a
different, more effective pathway,
early detection and interventions
may decrease incidence rates of
Neuroblastoma in children.
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